Diabetic Ulcer clinical trials at University of California Health
5 in progress, 4 open to eligible people
Bacteriophage Therapy in Patients With Diabetic Foot Osteomyelitis
open to eligible people ages 18-85
This is a phase IIa randomized trial designed to evaluate bacteriophage therapy in patients with diabetic foot osteomyelitis.
at UCLA
Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)
open to eligible people ages 18 years and up
This is a Phase 3, multicenter, randomized, double-blind, safety and efficacy study of contezolid acefosamil (IV)/contezolid (PO) compared with linezolid (IV and PO) administered for a total of 14 to 28 days in adult subjects with moderate or severe DFI.
at UCLA
Treatment With COMS One Device in Subjects With Diabetic Foot Ulcers
open to eligible people ages 22-90
The purpose of this clinical trial is to evaluate the safety and effectiveness of the treatment with the COMS One device in subjects with refractory diabetic foot ulcers (DFUs). The prospective randomized, double-blinded, sham-controlled trial is designed to demonstrate superiority of wound closure of the COMS One device to a sham-control device at 12 weeks post-application, when each is administered in conjunction with standard of care (SOC) in the treatment of DFUs.
at UCLA
Adjunct Collection of Additional Biorepository Data From Patients Enrolled in Diabetic Foot Consortium (DFC) Trials
open to eligible people ages 18 years and up
The Biorepository will guide the Diabetic Foot Consortium (DFC) activities for collection and storing biosamples and data from participants enrolled in other current and future DFC research studies.
at UCSF
DFC 004 Biomarkers for Active Diabetic Foot Ulcers
Sorry, not currently recruiting here
This study is a platform study designed to efficiently test multiple biomarkers to identify diabetic foot ulcers (DFUs) with a higher potential for healing versus not healing that ultimately could be applied at the point of care to drive personalized management decisions, and to better inform clinical trials of wound healing interventions
at UCSF
Our lead scientists for Diabetic Ulcer research studies include Michael Conte, MD Aksone Nouvong, DPM Ashley Miller, MD.
Last updated: